SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.
NCT ID: NCT00545480
Last Updated: 2015-08-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
596 participants
INTERVENTIONAL
2006-07-31
2009-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
NCT02604836
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.
NCT00545207
A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)
NCT00545363
A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.
NCT00545051
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia
NCT00129623
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
ibandronate [Bonviva/Boniva]
150mg po monthly for 12 months (with feedback)
2
ibandronate [Bonviva/Boniva]
150mg po monthly for 12 months (without feedback)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ibandronate [Bonviva/Boniva]
150mg po monthly for 12 months (with feedback)
ibandronate [Bonviva/Boniva]
150mg po monthly for 12 months (without feedback)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* \>55 years of age;
* naive to bisphosphonate therapy, or lapsed bisphosphonate users \>=6 months.
Exclusion Criteria
* hypersensitivity to bisphosphonates;
* treatment with other drugs affecting bone metabolism;
* history of major upper gastrointestinal disease.
55 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Agen, , France
Aix-les-Bains, , France
Albert, , France
Amboise, , France
Amiens, , France
Amiens, , France
Andernos-les-Bains, , France
Andrézieux-Bouthéon, , France
Angers, , France
Angoulême, , France
Annecy, , France
Antibes, , France
Antony, , France
Arcachon, , France
Argeles, , France
Arles, , France
Armentières, , France
Auch, , France
Auray, , France
Aurillac, , France
Avignon, , France
Avranches, , France
Bayonne, , France
Beaumont S/oise, , France
Belfort, , France
Besançon, , France
Béziers, , France
Billère, , France
Blanquefort, , France
Bolbec, , France
Bordeaux, , France
Bordeaux, , France
Brest, , France
Bruz, , France
Caen, , France
Cagnes-sur-Mer, , France
Cannes, , France
Carpentras, , France
Cavaillon, , France
Cenon, , France
Chalon-sur-Saône, , France
Charenton-le-Pont, , France
Chartres, , France
Châlons-en-Champagne, , France
Chelles, , France
Chilly-Mazarin, , France
Choisy-le-Roi, , France
Clamart, , France
Clermont-Ferrand, , France
Clichy, , France
Clichy, , France
Colmar, , France
Cornebarrieu, , France
Davézieux, , France
Dax, , France
Décines-Charpieu, , France
Dijon, , France
Dole, , France
Fontaine, , France
Fontenay S/bois, , France
Gourdon, , France
Granville, , France
Grenoble, , France
Hyères, , France
Issy-les-Moulineaux, , France
Istres, , France
L'isle Sur Sorgue, , France
L'Union, , France
La Madeleine, , France
La Roche-sur-Yon, , France
La Rochelle, , France
La Trinité, , France
Lagny-sur-Marne, , France
Landivisiau, , France
Langon, , France
Laval, , France
Lavaur, , France
Le Mans, , France
Le Perreux-sur-Marne, , France
Les Mureaux, , France
Libourne, , France
Lille, , France
Lille, , France
Limoges, , France
Lisieux, , France
Longwy, , France
Loos, , France
Lorient, , France
Lyon, , France
Lyon, , France
Lyon, , France
Maisons-Alfort, , France
Mandelieu-la-Napoule, , France
Marignane, , France
Maromme, , France
Marseille, , France
Marseille, , France
Marseille, , France
Marseille, , France
Martigues, , France
Meaux, , France
Mennecy, , France
Meylan, , France
Mérignac, , France
Millau, , France
Miribel, , France
Montbrisson, , France
Montélimar, , France
Montgeron, , France
Montluçon, , France
Montpellier, , France
Mulhouse, , France
Muret, , France
Nancy, , France
Nantes, , France
Narbonne, , France
Neuilly-sur-Seine, , France
Nice, , France
Nîmes, , France
Nogent-le-Rotrou, , France
Noisy-le-Sec, , France
Oloron-Sainte-Marie, , France
Orléans, , France
Ormesson-sur-Marne, , France
Orthez, , France
Oyonnax, , France
Pantin, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Perpignan, , France
Plan-de-Cuques, , France
Poissy, , France
Poitiers, , France
Pont-à-Mousson, , France
Puteaux, , France
Quimper, , France
Reims, , France
Rennes, , France
Rochefort, , France
Ronchin, , France
Roquebrune-Cap-Martin, , France
Rouen, , France
Rueil-Malmaison, , France
Saint-Affrique, , France
Saint-Brieuc, , France
Saint-Doulchard, , France
Saint-Etienne, , France
Saint-Etienne, , France
Saint-Flour, , France
Saint-Jacques-de-la-Lande, , France
Saint-Lô, , France
Saint-Mandé, , France
Saint-Nazaire, , France
Saint-Pierre-de-Coutances, , France
Saint-Quentin, , France
Sainte-Maxime, , France
Saintes, , France
Sarrebourg, , France
Sartrouville, , France
Sedan, , France
Senlis, , France
Sélestat, , France
St-Malo, , France
Strasbourg, , France
Strasbourg, , France
Tassin-la-Demi-Lune, , France
Thionville, , France
Toulon, , France
Toulouse, , France
Toulouse, , France
Toulouse, , France
Tourcoing, , France
Tournon-sur-Rhône, , France
Tours, , France
Valenciennes, , France
Vandœuvre-lès-Nancy, , France
Vence, , France
Vernet-les-Bains, , France
Vénissieux, , France
Villeneuve-sur-Lot, , France
Villeurbanne, , France
Vincennes, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Roux C, Giraudeau B, Rouanet S, Dubourg G, Perrodeau E, Ravaud P. Monitoring of bone turnover markers does not improve persistence with ibandronate treatment. Joint Bone Spine. 2012 Jul;79(4):389-92. doi: 10.1016/j.jbspin.2011.05.001. Epub 2011 Jun 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML19358
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.